440 related articles for article (PubMed ID: 3164788)
1. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
Manninen V; Elo MO; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
JAMA; 1988 Aug; 260(5):641-51. PubMed ID: 3164788
[TBL] [Abstract][Full Text] [Related]
2. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
[TBL] [Abstract][Full Text] [Related]
3. The Helsinki Heart Study: basic design and randomization procedure.
Mänttäri M; Elo O; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
Eur Heart J; 1987 Oct; 8 Suppl I():1-29. PubMed ID: 3322826
[TBL] [Abstract][Full Text] [Related]
4. Relation between baseline lipid and lipoprotein values and the incidence of coronary heart disease in the Helsinki Heart Study.
Manninen V; Huttunen JK; Heinonen OP; Tenkanen L; Frick MH
Am J Cardiol; 1989 May; 63(16):42H-47H. PubMed ID: 2650524
[TBL] [Abstract][Full Text] [Related]
5. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
[TBL] [Abstract][Full Text] [Related]
6. Helsinki Heart Study. New perspectives in the prevention of coronary heart disease.
Huttunen JK; Frick MH; Heinonen OP; Heinsalmi P; Manninen V; Mänttäri M; Romo M
Drugs; 1988; 36 Suppl 3():32-6. PubMed ID: 3076118
[TBL] [Abstract][Full Text] [Related]
7. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Rubins HB; Robins SJ; Collins D; Fye CL; Anderson JW; Elam MB; Faas FH; Linares E; Schaefer EJ; Schectman G; Wilt TJ; Wittes J
N Engl J Med; 1999 Aug; 341(6):410-8. PubMed ID: 10438259
[TBL] [Abstract][Full Text] [Related]
8. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease. Effects on metabolism of low-density lipoproteins.
Vega GL; Grundy SM
JAMA; 1985 Apr; 253(16):2398-403. PubMed ID: 3856692
[TBL] [Abstract][Full Text] [Related]
9. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.
Manninen V; Tenkanen L; Koskinen P; Huttunen JK; Mänttäri M; Heinonen OP; Frick MH
Circulation; 1992 Jan; 85(1):37-45. PubMed ID: 1728471
[TBL] [Abstract][Full Text] [Related]
10. Combination drug therapy for familial combined hyperlipidemia.
East C; Bilheimer DW; Grundy SM
Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
[TBL] [Abstract][Full Text] [Related]
11. Lipoproteins and coronary heart disease in the Helsinki Heart Study.
Mänttäri M; Huttunen JK; Koskinen P; Manninen V; Tenkanen L; Heinonen OP; Frick MH
Eur Heart J; 1990 Dec; 11 Suppl H():26-31. PubMed ID: 2073911
[TBL] [Abstract][Full Text] [Related]
12. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
Koskinen P; Mänttäri M; Manninen V; Huttunen JK; Heinonen OP; Frick MH
Diabetes Care; 1992 Jul; 15(7):820-5. PubMed ID: 1516498
[TBL] [Abstract][Full Text] [Related]
13. The Gemfibrozil Study.
Manninen V
Acta Med Scand Suppl; 1985; 701():83-8. PubMed ID: 3907298
[TBL] [Abstract][Full Text] [Related]
14. Lessons from the Helsinki Heart Study. Fibric acid therapy for dyslipidemia.
Grundy SM
Postgrad Med; 1988 Jul; 84(1):217-8, 223-31. PubMed ID: 3164473
[No Abstract] [Full Text] [Related]
15. Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia.
Athyros VG; Papageorgiou AA; Avramidis MJ; Kontopoulos AG
Coron Artery Dis; 1995 Mar; 6(3):251-6. PubMed ID: 7788039
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study of the month. Usefulness of increasing HDL cholesterol in secondary prevention of coronary heart disease: results of the VA-HIT study].
Scheen AJ
Rev Med Liege; 1999 Sep; 54(9):773-5. PubMed ID: 10589275
[TBL] [Abstract][Full Text] [Related]
17. Gemfibrozil, lipids, and coronary risk.
Rifkind BM
N Engl J Med; 1987 Nov; 317(20):1279-81. PubMed ID: 3313042
[No Abstract] [Full Text] [Related]
18. Gemfibrozil in the treatment of dyslipidaemia. A 5-year follow-up study.
Manninen V; Mälkönen M; Eisalo A; Virtamo J; Tuomilehto J; Kuusisto P
Acta Med Scand Suppl; 1982; 668():82-7. PubMed ID: 6762809
[No Abstract] [Full Text] [Related]
19. Clinical results with gemfibrozil and background to the Helsinki Heart Study.
Manninen V
Am J Cardiol; 1983 Aug; 52(4):35B-38B. PubMed ID: 6351578
[No Abstract] [Full Text] [Related]
20. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
Hay JW; Sterling KL
Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
